10-Q: The Greater Cannabis Company Reports Second Quarter 2024 Results Amidst Ongoing Financial Challenges

The Greater Cannabis Company reported no revenue and a net loss of $89,528 for the six months ended June 30, 2024, while continuing to address going concern issues.

Summary

• The Greater Cannabis Company reported its financial results for the second quarter of 2024, showing no revenue for both the three and six-month periods ending June 30, 2024.
• The company's operating expenses for the six months ended June 30, 2024, were $78,208, a slight decrease from $80,872 in the same period of 2023.
• The net loss for the six months ended June 30, 2024, was $89,528, compared to a net loss of $88,111 for the same period in 2023.
• The company's cash balance decreased from $166,859 at the end of 2023 to $80,316 as of June 30, 2024.
• The company continues to face challenges related to its ability to continue as a going concern, with significant liabilities and negative working capital.
• The company is focused on developing and commercializing a novel cannabinoid therapeutic and exploring cannabis-related investment opportunities.

Sentiment

Score: 2

Explanation: The document indicates a very negative sentiment due to the lack of revenue, significant losses, decreasing cash balance, and substantial doubt about the company's ability to continue as a going concern. The company's reliance on future funding and the risks associated with its business model further contribute to the low sentiment score.

Positives

• Operating expenses saw a slight decrease compared to the same period last year.
• The company is actively pursuing the development of a novel cannabinoid therapeutic.
• The company is exploring various cannabis-related investment and development opportunities.

Negatives

• The company reported no revenue for the current reporting period.
• The company experienced a net loss of $89,528 for the six months ended June 30, 2024.
• The company's cash balance has significantly decreased.
• The company has a negative working capital of $753,677.
• There is substantial doubt about the company's ability to continue as a going concern.

Risks

• The company faces the risk of not being able to remediate material weaknesses in internal controls.
• There is a risk that the company will fail to meet the requirements of agreements under which it acquired business interests.
• The company may be unable to secure additional financing to sustain its growth plans.
• The company faces risks related to attracting and retaining qualified personnel.
• The company's profitability is uncertain due to its history of losses.
• There is a risk of failure to obtain adequate financing on a timely basis for planned development projects.
• The company faces risks related to environmental regulation and tax assessments.

Future Outlook

The company plans to conduct clinical studies on its cannabinoid-based therapeutic and concentrate on cannabis-related investment and development opportunities.

Management Comments

• Management is focused on developing and commercializing a novel cannabinoid therapeutic.
• Management is exploring cannabis-related investment and development opportunities.

Industry Context

The company is operating in the competitive cannabis and biotechnology sectors, focusing on cannabinoid therapeutics, which is a growing area of interest in the pharmaceutical industry.

Comparison to Industry Standards

• The company's lack of revenue is a significant deviation from industry norms for companies that have launched products.
• The company's high operating expenses relative to its lack of revenue is not sustainable and is a concern.
• The company's cash burn rate is high and needs to be addressed.
• The company's focus on clinical studies is similar to other biotech companies in the sector, but the lack of funding is a major concern.
• The company's reliance on debt financing is a risk, especially given the going concern issues.

Related Party Transactions

• Loans payable to related parties include $180,000 from Elisha Kalfa and Yonah Kalfa and $80,000 from Fernando Bisker and Sigalush, LLC.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern issues.
• Employees may be impacted by potential layoffs or business curtailment if the company cannot secure additional funding.
• Creditors face the risk of non-payment due to the company's financial difficulties.
• Customers are not currently impacted as the company has no revenue.

Next Steps

• The company plans to conduct clinical studies on its cannabinoid-based therapeutic.
• The company will concentrate on cannabis-related investment and development opportunities.
• The company needs to secure additional funding to continue operations.

Key Dates

Keywords

cannabis, cannabinoid therapeutics, financial results, net loss, operating expenses, going concern, clinical studies, investment, biotechnology, drug delivery